Indoleamine 2,3 Dioxygenase 1 Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52 Pipeline Review, H2 2018
Summary
Indoleamine 2,3 Dioxygenase 1 Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52 pipeline Target constitutes close to 39 molecules. Out of which approximately 35 molecules are developed by companies and remaining by the universities/institutes. The latest report Indoleamine 2,3 Dioxygenase 1 Pipeline Review, H2 2018, outlays comprehensive information on the Indoleamine 2,3 Dioxygenase 1 Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Indoleamine 2,3 Dioxygenase 1 Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52 Indoleaminepyrrole 2, 3dioxygenase 1 is a hemecontaining enzyme encoded by the IDO1 gene. This enzyme acts on multiple tryptophan substrates including Dtryptophan, Ltryptophan, 5hydroxytryptophan, tryptamine, and serotonin. This enzyme plays a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity.
The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 9, 3, 14 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Immunology and Metabolic Disorders which include indications Solid Tumor, NonSmall Cell Lung Cancer, Metastatic Melanoma, Glioblastoma Multiforme GBM, Bladder Cancer, Colon Cancer, Gastric Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Lung Cancer, Pancreatic Ductal Adenocarcinoma, Renal Cell Carcinoma, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Adenocarcinoma, Alopecia, Brain Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Diffuse Large BCell Lymphoma, Endometrial Cancer, Ependymoma, Glioma, Gliosarcoma, Hematological Tumor, Hepatocellular Carcinoma, HighGrade Glioma, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Liver Cancer, Malignant Glioma, Medulloblastoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Metastatic Renal Cell Carcinoma, Metastatic Transitional Urothelial Tract Cancer, Muscle Invasive Bladder Cancer MIBC, Non Muscle Invasive Bladder Cancer NMIBC Superficial Bladder Cancer, Ocular Melanoma, Ovarian Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Psoriasis, Rectal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Squamous Cell Carcinoma, Transitional Cell Cancer Urothelial Cell Cancer and Type 1 Diabetes Juvenile Diabetes.
Furthermore, this report also reviews key players involved in Indoleamine 2,3 Dioxygenase 1 Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Indoleamine 2,3 Dioxygenase 1 Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52
The report reviews Indoleamine 2,3 Dioxygenase 1 Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Indoleamine 2,3 Dioxygenase 1 Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52 targeted therapeutics and enlists all their major and minor projects
The report assesses Indoleamine 2,3 Dioxygenase 1 Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Indoleamine 2,3 Dioxygenase 1 Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Indoleamine 2,3 Dioxygenase 1 Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Indoleamine 2,3 Dioxygenase 1 Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope